Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founders in connection with Polaris’ investment in Distriktstandvården
Mandate

Vinge advises the founders in connection with Polaris’ investment in Distriktstandvården

September 01, 2020 Employment and Benefits M&A

Vinge advises the founders of Distriktstandvården Ibbe Gnem and Jan Lindqvist in connection with Polaris’ investment in the company.

Distriktstandvården is the leading independent private dentistry chain in the greater Stockholm region. In addition to general, emergency and aesthetic dentistry services, Distriktstandvården offers specialist dental care as well as mobile and anaesthesia treatments. Following the investment, Polaris becomes a co-owner of Distriktstandvården alongside its founders who founded the company in 2010.

Vinge’s team consisted of Jonas Johansson, Matthias Pannier, Carl Sander, Nina Gransäter and Hanna Risberg (M&A), Ebba Svenburg (Employment), and VDR-specialists Jessica Öijer and Christoffer Widström.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024